A sweeping new analysis of more than a quarter century of American death records has found that while the absolute number of people dying from motor neuron disease in the United States has climbed steadily, the age-adjusted mortality rate has remained essentially flat. The study, published in BMC Public Health, examined 170,570 deaths attributed to motor neuron disease among US adults aged 25 years and older between 1999 and 2024, drawing on the Centers for Disease Control and Prevention’s Wide-ranging Online Data for Epidemiologic Research database, better known as CDC WONDER. The findings offer one of the most complete long-term portraits yet of how this devastating family of neurodegenerative conditions is shaping mortality across the country, and they carry important implications for how health systems prepare for the growing care needs of an aging population.
Motor neuron disease encompasses a group of progressive disorders in which the nerve cells that control voluntary muscle movement degenerate and die. The most familiar form is amyotrophic lateral sclerosis, or ALS, but the category also includes other rarer variants. In the study, researchers identified deaths using the International Classification of Diseases, 10th Revision code G12.2 listed as the underlying cause of death. Over the 26-year study window, annual deaths rose from 5,121 in 1999 to 7,551 in 2024, a 47.45 percent increase. On its face, that trajectory might suggest an escalating epidemic. Yet when the researchers adjusted for the changing age structure of the population, a different picture emerged: the age-adjusted mortality rate actually declined slightly, from 2.87 to 2.58 deaths per 100,000 population.
The gap between raw counts and adjusted rates is one of the most instructive technical points in the analysis. Because the American population has aged considerably since 1999, with a rapidly expanding share of adults in the age brackets where motor neuron disease is most common, raw death counts naturally rise even if an individual’s underlying risk does not. Age-adjusted mortality rates correct for this demographic shift by applying observed age-specific death rates to a standard population, allowing like-for-like comparisons across time. The authors used joinpoint regression, a statistical technique that identifies points in time where trends change direction, to estimate annual percentage changes and average annual percentage changes. The result: an overall average annual percentage change of minus 0.50 percent, with a 95 percent confidence interval spanning from minus 1.24 to plus 0.24 percent, a range that includes zero and therefore indicates no statistically clear long-term increase or decrease.
Beneath that overall stability, however, the mortality burden was far from evenly distributed. Deaths were heavily concentrated among adults aged 65 years and older, among men, and among non-Hispanic White individuals. These demographic patterns are consistent with much of the prior epidemiological literature on motor neuron disease, which has repeatedly noted both older age at onset and a modest male predominance. For age-group analyses, the researchers used crude mortality rates specific to each age band, since age adjustment is unnecessary when comparing within a single age stratum. For all other stratifications, including sex, race and ethnicity, census region, state, and level of urbanization, the age-adjusted mortality rate served as the primary metric.
Geography told its own revealing story. The South recorded the largest total number of motor neuron disease deaths, a finding shaped partly by the sheer size of that region’s population. But when rates rather than counts were compared, it was the Midwest that carried the highest age-adjusted mortality rate. The distinction matters: total counts reflect population size, while rates reflect underlying risk after demographic correction. A parallel pattern emerged along the urban-rural divide. In analyses covering 1999 through 2020, the most recent period for which urbanization classifications were available, age-adjusted mortality rates were consistently higher in nonmetropolitan areas than in metropolitan ones. The authors stress, however, that these stratified and state-level results should be interpreted as descriptive and exploratory rather than as evidence of causal differences between places.
Why might rural areas show elevated rates? The study itself does not test explanations, but the rural-metropolitan gap aligns with plausible hypotheses that researchers have long considered, including differences in occupational exposures, environmental factors, healthcare access, and diagnostic patterns. Rural populations tend to be older on average, and access to neuromuscular specialists and advanced diagnostic resources is often thinner outside major metropolitan centers, factors that could influence both true disease occurrence and the likelihood that a death is correctly attributed to motor neuron disease on a death certificate. Death-certificate data, while invaluable for tracking long-term and geographic patterns, are inherently subject to coding practices that may vary across providers, regions, and eras.
The methodological architecture of the study is worth appreciating. CDC WONDER aggregates Underlying Cause of Death data from the National Center for Health Statistics, providing publicly available, anonymous, aggregate-level mortality records covering the entire United States. Because the data are de-identified and population-level, the analysis required no institutional review board approval and involved no contact with individual participants. Serial cross-sectional designs like this one examine the population at repeated time points, stitching together annual snapshots into a long-term trend line. The trade-off is that such designs capture mortality patterns but cannot follow individuals forward in time, which limits causal inference. The authors are explicit that their findings describe patterns, not mechanisms, and that the state-level and stratified results are exploratory.
The practical implications lean heavily toward planning and resource allocation. The authors conclude that even with stable age-adjusted rates, the needs associated with motor neuron disease-related medical care, respiratory support, rehabilitation management, and public health services are likely to keep growing as the population ages. Motor neuron disease is relentlessly progressive: as motor neurons die, patients lose the ability to walk, speak, swallow, and eventually breathe, making multidisciplinary care, ventilatory support, and rehabilitation central to management. A rising volume of cases, driven by demography rather than by any change in per-person risk, translates directly into rising demand for neurologists, pulmonologists, respiratory therapists, physical and occupational therapists, palliative care teams, and caregiver support networks, particularly in the regions and community types where the registered burden is heaviest.
The study also illustrates a broader lesson for how health statistics should be read in an aging society. Raw counts of deaths from age-related diseases will climb in nearly every developed country simply because more people are living into the risk window. Age-adjusted rates are the tool that separates real changes in risk from demographic arithmetic, and here they suggest that the United States has not experienced a clear long-term escalation in motor neuron disease mortality risk per person over the past quarter century. That is not a cause for complacency; the absolute and growing number of affected families, the concentrated burden among older adults, and the persistent geographic and demographic disparities all demand sustained attention. But it reframes the narrative: America’s motor neuron disease challenge is primarily a story of population aging and uneven distribution, not of a sharply worsening underlying toll.
For researchers, the analysis sets a benchmark against which future studies can be measured. The slightly declining point estimate, with confidence intervals that straddle zero, leaves open the possibility of small increases or small decreases that larger or more granular datasets might resolve. Continued surveillance will be needed to track whether the expansion of therapies for ALS, improvements in supportive and respiratory care, and lengthening survival times alter mortality patterns in the decades ahead, since better management can extend life and, paradoxically, reshape how deaths are counted and classified. For now, the study provides clinicians, policymakers, and public health planners with a rigorous, nationally representative map of where and among whom motor neuron disease deaths occur, and a clear signal that the systems built to care for these patients must scale with the demographics of the country rather than with the per-capita rate alone.
One nuance worth noting is that the underlying cause of death on a certificate may not capture the full contribution of motor neuron disease to a person’s decline. Because respiratory failure is the usual terminal event, some deaths in which the condition was a contributing factor may be coded to other causes, meaning the figures here likely represent a conservative floor rather than a ceiling of the true mortality burden. The restriction to a single ICD-10 code also means that deaths classified under related codes would fall outside the count, a limitation the authors implicitly acknowledge by framing their results around registered mortality.
The demographic concentration among non-Hispanic White individuals also invites careful reading. Such patterns can reflect a mix of true differences in disease occurrence, differences in age structure across racial and ethnic groups, and differences in diagnostic access and certification practices. Disentangling those threads requires data sources richer than aggregate death records, such as population-based disease registries that capture incidence, survival, and treatment exposure rather than death alone.
Finally, the flat age-adjusted trend should not be read as evidence that the disease itself is static. Advances in multidisciplinary care, nutritional support, and respiratory management have gradually altered the natural history of these conditions, and longer survival can shift where and when deaths are recorded. Continued monitoring, ideally complemented by registry-based and clinical data, will be essential to interpret how evolving care patterns reshape the mortality landscape described here.
Subject of Research: Long-term mortality trends and geographic disparities in motor neuron disease among US adults from 1999 to 2024
Article Title: Mortality trends and geographic disparities in motor neuron disease among US adults aged 25 years and older, 1999–2024: a serial cross-sectional study using CDC WONDER
Article References: Jiang, R., Zhu, Q., Jiang, Q., Zhao, T., & Zhou, J. (2026). Mortality trends and geographic disparities in motor neuron disease among US adults aged 25 years and older, 1999–2024: a serial cross-sectional study using CDC WONDER. BMC Public Health. https://doi.org/10.1186/s12889-026-29374-x
Image Credits: AI Generated
DOI: 10.1186/s12889-026-29374-x
Keywords: motor neuron disease, amyotrophic lateral sclerosis, mortality trends, CDC WONDER, age-adjusted mortality rate, geographic disparities, BMC Public Health, joinpoint regression, rural health, neurodegenerative disease, population aging, public health
Cite Scienmag News
APA MLA Chicago
Cassandra Pierce. (September 12, 2026). Motor Neuron Disease Deaths Rise in the US, but Age-Adjusted Rates Hold Steady. Scienmag. https://scienmag.com/motor-neuron-disease-deaths-rise-in-the-us-but-age-adjusted-rates-hold-steady/
Cassandra Pierce. “Motor Neuron Disease Deaths Rise in the US, but Age-Adjusted Rates Hold Steady.” Scienmag, 12 September 2026, https://scienmag.com/motor-neuron-disease-deaths-rise-in-the-us-but-age-adjusted-rates-hold-steady/. Accessed 12 September 2026.
Cassandra Pierce. “Motor Neuron Disease Deaths Rise in the US, but Age-Adjusted Rates Hold Steady.” Scienmag. September 12, 2026. https://scienmag.com/motor-neuron-disease-deaths-rise-in-the-us-but-age-adjusted-rates-hold-steady/
Copy citation Download RIS
Tags: age-adjusted death rates for ALS and neurodegenerative disordersage-adjusted mortality rateamyotrophic lateral sclerosisBMC Public HealthCDC WONDERCDC WONDER database for neurodegenerative disease researchdemographic factors influencing neurodegenerative disease mortalityepidemiology of amyotrophic lateral sclerosis in the USgeographic disparitieshealthcare implications of rising motor neuron disease deathsimpact of aging population on motor neuron disease prevalencejoinpoint regressionlong-term analysis of US death records for motor neuron diseaselong-term trends in motor neuron disease survival ratesmortality trendsmotor neuron diseasemotor neuron disease mortality trends in the USneurodegenerative diseaseneurodegenerative diseases andpopulation agingPublic healthrural health
